Diabetes and the Heart
Cardiometabolic Screening and
Hospital Care
 |
||
 |
||
|
How to Obtain AMA PRA
|
|
 |
||
Release Date: November 12, 2009
Renewal Date: November 12, 2011
Expiration Date: November 12, 2012
Estimated Time of Completion: 2 hours, 45 minutes
Description
The Diabetes and the Heart webcast series is composed of selected presentations from Diabetes and the Heart: A Clinical Summit on Critically Challenging Patients, a live symposium held August 6-7, 2009. The Summit was the inaugural educational activity of the Joslin Diabetes Center and Cleveland Clinic partnership.
With the increase in prevalence of the cardiometabolic syndrome and its comorbidities, the need to optimize preventive and therapeutic interventions is a major focus of most clinicians in primary care. Certainly, clinicians must recognize the signs and symptoms of the cardiometabolic syndrome and initiate early and effective preventive interventions. However, timely diagnosis and appropriate treatment are equally as important to reduce eventual morbidity and mortality.
Learning Objectives
- Describe the characteristics and pathophysiology of dyslipidemia associated with diabetes.
- Discuss the rationale of established and emerging therapeutic strategies to achieve optimal lipid goals to reduce cardiovascular events.
- Discuss the possible mechanisms underlying glucose toxicity in the acute care situation.
- Explain the physiologic mechanisms underlying the benefit of insulin in the acute care setting.
- Review the pathophysiology of diabetic nephropathy and its treatment.
- Recognize chronic kidney disease as an independent risk factor for cardiovascular disease.
- Review the modifiable cardiovascular risks other than glucose levels for patients with diabetes.
Target Audience
Primary care physicians, endocrinologists, cardiologists, nurse practitioners, physician assistants, nurses and other allied healthcare professionals will find this webcast valuable in their daily practice.
Accreditation
The Cleveland Clinic Foundation Center for Continuing Education is accredited by the
Accreditation Council for Continuing Medical Education to provide continuing medical
education for physicians.
The Cleveland Clinic Foundation Center for Continuing Education designates this educational activity for a maximum of 2.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Participants claiming CME credit from this activity may submit the credit hours to the American Osteopathic Association Council on Continuing Medical Education for Category 2 credit.
Activity Directors| Richard S. Beaser, MD Medical Executive Director of Professional Education Joslin Diabetes Center Boston, MA |
James B. Young, MD Institute Chairman Endocrinology and Metabolism Institute Cleveland Clinic Cleveland, OH |
Robert S. Zimmerman, MD Director, Fellowship Program Endocrinology and Metabolism Institute Cleveland Clinic Cleveland, OH |
Faculty
| Om P. Ganda, MD Director, Lipid Center Joslin Diabetes Center Associate Clinical Professor of Medicine Harvard Medical School Boston, MA |
Adi Mehta, MD, FACE Endocrinology and Metabolism Institute Cleveland Clinic Cleveland, OH |
Joseph Nally, MD Glickman Urological and Kidney Institute Cleveland Clinic Cleveland, OH |
Leann Olansky, MD Endocrinology and Metabolism Institute Cleveland Clinic Cleveland, OH |
Disclosures
In accordance with the Standards for Commercial Support issued by the Accreditation
Council for Continuing Medical Education (ACCME), The Cleveland Clinic Foundation
Center for Continuing Education requires resolution of all faculty conflicts of interest to
ensure CME activities are free of commercial bias.
The following faculty have indicated that they may have a relationship which, in the context of their presentation, could be perceived as a potential conflict of interest:
| Om P. Ganda, MD | |||
| Takeda Pharmaceuticals | Board Membership and Consulting | ||
| Abbott Pharmaceuticals | Teaching and Speaking | ||
| Adi Mehta, MD, FACE | Eli Lilly; Merck & Company; Novo Nordisk | Teaching and Speaking | |
| James B. Young, MD | |||
| AstraZeneca; Gilead Sciences, Inc.; GlaxoSmithKline | Consulting | ||
| AstraZeneca | Independent Contractor | ||
| AstraZeneca; Gilead Sciences, Inc.; GlaxoSmithKline | Review Panels | ||
| Robert S. Zimmerman, MD | |||
| GlaxoSmithKline; Novo Nordisk | Teaching and Speaking | ||
The following faculty have indicated that they have no relationship which, in the context of their presentation, could be perceived as a potential conflict of interest:
Richard S. Beaser, MD
Joseph Nally, MD
Leann Olansky, MD
The Cleveland Clinic Foundation Center for Continuing Education
acknowledges educational grants for partial support of this activity from:
Amylin Pharmaceuticals, Inc. and Lilly USA, LLC
Athena Diagnostics, Inc.
Daiichi Sankyo, Inc.
Merck & Co., Inc.
St. Jude Medical
This CME activity was produced by
the Cleveland Clinic Endocrinology and Metabolism Institute,
the Center for Continuing Education, and the Joslin Diabetes Center.
